A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates.

Phase 1

• Conditions: Postmenopausal osteoporosis; MedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausal

• Registration Number: EUCTR2009-010726-19-FR
• Lead Sponsor: Amgen Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-07-10
• Study Completion: 2011-11-09
• Last Update Posted: 18 October 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 800

Inclusion Criteria

Subjects will meet all of the following inclusion criteria prior to enrollment:

Ambulatory, postmenopausal women (based on medical history) 55 years or older at screening
• Postmenopause will be defined as no vaginal bleeding or spotting for at least 12 months
- If the subject is 55 – 60 years old and there is uncertainty regarding menopausal status, confirmation of serum FSH (= 50 mIU/mL) and serum estradiol (= 20 pg/mL) must be obtained
- If the subject is greater than 60 years old, evaluation of FSH and estradiol levels is not needed to confirm menopausal status

Have received their first prescription of daily or weekly bisphosphonate therapy at least 6 months but no more than 18 months prior to screening

May have received
• raloxifene, calcitonin, prior to initiation of bisphosphonate therapy.
• calcium, and vitamin D
• Hormone replacement therapy (e.g. estrogen use for mitigation of menopausal
symptoms)

Subject has:
• Stopped bisphosphonate therapy (is denoted as non-persistent) at least one month before the screening visit, or
• Demonstrated low adherence to therapy assessed by a score of less than 6 on the OS-MMAS

Screening BMD (g/cm2) values, at the lumbar spine OR total hip, that occur within the following ranges, based on the particular scanner that is used:

GE Lunar Hologic
Lumbar spine 0.700 =BMD =0.940 0.607=BMD =0.827
Total hip 0.504 =BMD =0.756 0.454 =BMD =0.698

Both the initial and the repeat DXA scan of the lumbar spine OR the total hip must meet the above eligibility criteria.

At least 2 lumbar vertebrae must be evaluable by DXA.

At least one hip must be evaluable by DXA (eg, no history of either bilateral hip replacement or pins in both hips)

Provide signed informed consent before any study-specific procedures are conducted
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Subjects meeting any of the following criteria are not eligible for participation in the study:

Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures

Current use of medications prescribed for osteoporosis treatment other than oral daily or weekly bisphosphonate

Contraindicated to receive oral ibandronate 150 mg PO QM, including
• Hypersensitivity to ibandronate 150 mg PO QM or other constituents of ibandronate 150 mg PO QM tablets
• Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia
• Inability to stand or sit upright for at least 60 minutes

Administration of any of the following treatments within 3 months of screening
• Tibolone
• Anabolic steroids or testosterone
• Glucocorticosteroids (= 5 mg prednisone equivalent per day for more than 10 days or a total cumulative dose of = 50 mg)

Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)] - Repletion will be allowed and subjects may be re-screened

Evidence of any of the following per subject report, chart review or central laboratory result:
• Significantly impaired renal function as determined by estimated Glomerular Filtration Rate less that 30mL/min/1.73 m2
• Current hypo- or hypercalcemia based on the central laboratory reference ranges
• Active gastric or duodenal ulcer; or any history of significant gastrointestinal bleed requiring hospitalization or transfusion
• Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen
• Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years
• Any metabolic bone disease or secondary cause of bone loss that is not controlled and may interfere with the interpretation of the findings

Previous participation in clinical trials with denosumab 60 mg SC Q6M (regardless of treatment)

Received any solid organ or bone marrow transplant

Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results

Known sensitivity to mammalian cell derived drug products

Known intolerance to calcium supplements

Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s)

Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results

Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To evaluate the change in total hip Bone Mineral Density (BMD) at 12 months in postmenopausal women transitioning from previous daily or weekly bisphosphonate therapy to denosumab 60 mg SC Q6M compared to that in subjects transitioning to ibandronate 150mg PO QM.<br><br>Safety Objectives: To evaluate safety and tolerability measured by evaluating adverse events, antidenosumab antibodies and laboratory analytes over 12 months.<br>;Secondary Objective: To evaluate the effects of transitioning to denosumab 60 mg SC Q6M in comparison to transitioning to ibandronate 150 mg PO QM on<br><br>• Serum type 1 C-Telopeptide-1 (sCTX-1) levels at 1 month (in a subset of subjects)<br>• BMD at the femoral neck at 12 months<br>• BMD at the lumbar spine at 12 months;Primary end point(s): Percent change from baseline in BMD at the total hip at 12 months.